References
- Shimamoto K, Ando K, Fujita T, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res. 2014;37:253–390.
- Rakugi H, Enya K, Sugiura K, et al. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res. 2012;35:552–558.
- Wang AL, Iadecola C, Wang G. New generations of dihydropyridines for treatment of hypertension. J Geriatr Cardiol. 2017;14:67–72.
- Derosa G, Maffioli P. Drug safety evaluation of amlodipine. Expert Opin Drug Saf. 2011;10:795–804.
- Rakugi H, Nakata E, Sasaki E, et al. Evaluation of the efficacy and tolerability of fixed-dose combination therapy of azilsartan and amlodipine besylate in Japanese patients with grade I to II essential hypertension. Clin Ther. 2014;36:711–721.
- Padilla MC, Armas-Hernández MJ, Hernández RH, et al. Update of diuretics in the treatment of hypertension. Am J Ther. 2007;14:154–160.
- Oshikawa J, Toya Y, Morita S, et al. Angiotensin receptor blocker (ARB)-diuretic versus ARB-calcium channel blocker combination therapy for hypertension uncontrolled by ARB monotherapy. Clin Exp Hypertens. 2014;36:244–250.
- Evaluation and Licensing Division, Pharmaceutical Affairs Bureau, Ministry of Health, Labour and Welfare. Extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions. PAB/ELD Notification No. 592 (May 24, 1995).
- Xie L, Frech-Tamas F, Marrett E, et al. A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy. Curr Med Res Opin. 2014;30:2415–2422.
- Bramley TJ, Gerbino PP, Nightengale BS, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. Jmcp. 2006;12:239–245.
- Fung V, Huang J, Brand R, et al. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther. 2007;29:972–984.
- Ho PM, Magid DJ, Shetterly SM, et al. Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease. Arch Intern Med. 2008;168:271–276.
- Yiannakopoulou ECh, Papadopulos JS, Cokkinos DV, et al. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil. 2005;12:243–249.
- Bailey JE, Wan JY, Tang J, et al. Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J Gen Intern Med. 2010;25:495–503.
- Cherry SB, Benner JS, Hussein MA, et al. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health. 2009;12:489–497.
- Dragomir A, Côté R, Roy L, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48:418–425.
- Kettani FZ, Dragomir A, Côté R, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009;40:213–220.
- Perreault S, Dragomir A, White M, et al. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med. 2009;266:207–218.